rethinkTHC Search
Menu
Study breakdown

CBD Reduced Opioid Self-Administration in Rats Without Reducing Pain Relief

ObservationalPreliminary evidence
The takeaway

In rats with neuropathic pain, CBD reduced opioid-seeking behavior without diminishing oxycodone's pain-relieving effects—suggesting CBD could help prevent opioid misuse while preserving analgesia.

Pain medicine researchers, addiction scientists, and clinicians looking for ways to reduce opioid misuse risk in chronic pain patients.

What the researchers found

This study addresses one of the most pressing questions in pain medicine: can we reduce opioid misuse without taking away pain relief?

Rats were trained to self-administer oxycodone (pressing a lever to receive intravenous doses), then given chronic neuropathic pain via sciatic nerve injury. CBD was administered at various doses (1, 3, and 10 mg/kg) before self-administration sessions, with pain testing afterward.

The key finding: CBD reduced oxycodone self-administration without reducing oxycodone's analgesic effects. The rats pressed the lever less for opioids but still got the same pain relief from what they did take. This is the best of both worlds—less drug-seeking behavior with preserved pain management.

Interesting nuance: the neuropathic pain injury alone didn't increase oxycodone self-administration, suggesting that pain itself doesn't automatically drive opioid-seeking behavior in this model—the self-administration reflects the reinforcing (rewarding) properties of the drug rather than pain-driven use.

CBD has no known abuse liability and is non-intoxicating, making it an attractive candidate adjunct for patients on chronic opioid therapy. If this finding translates to humans, CBD could be added to opioid regimens to reduce the reinforcing properties that drive misuse while maintaining pain control.

Why it matters

The opioid crisis has made clinicians wary of prescribing opioids for chronic pain, sometimes undertreating pain in the process. If CBD can reduce the rewarding/addictive properties of opioids without diminishing analgesia, it could allow safer opioid prescribing for the patients who genuinely need them. This is a harm reduction approach at the pharmacological level.

The numbers in context

Oxycodone: 0.06 mg/kg/infusion IV. CBD doses: 1, 3, 10 mg/kg IP. CBD reduced active lever pressing (opioid-seeking). CCI confirmed by reduced paw withdrawal latency. Oxycodone analgesia preserved despite reduced self-administration.

How the study worked

Animal study. Adult male rats trained to self-administer IV oxycodone (0.06 mg/kg/infusion). Chronic constriction injury (CCI) of sciatic nerve to induce neuropathic pain. Paw withdrawal latency (Hargreaves test) for thermal pain. CBD (0, 1, 3, 10 mg/kg, IP) administered before self-administration sessions, pain testing afterward.

Who was studied

Adult male Sprague-Dawley rats, specific details on total number not provided.

What this study cannot tell us

Rat model—human opioid-seeking behavior involves psychological and social factors not captured in lever-pressing paradigms. Only male rats used. The CBD was administered by the researchers (not self-selected), which doesn't model how patients would actually use CBD alongside opioids. IV oxycodone self-administration is more pharmacokinetically intense than oral opioid use. Acute CBD effects may differ from chronic co-administration.

How to read the evidence

Preclinical study with a well-designed self-administration model—strong for mechanism but requires human clinical trials.

When this study was published

Published in 2026 in Scientific Reports, addressing the intersection of the opioid crisis and cannabinoid research.

The bigger picture

This directly connects to RTHC-00161's finding that medical marijuana access reduced strong opioid prescriptions after cancer surgery—CBD specifically reducing opioid-seeking provides a potential mechanism. RTHC-00225's Cochrane Review of cannabis for neuropathic pain found modest analgesic effects; this study suggests a different role—not replacing opioids but making them safer. RTHC-00200's finding that CBG reduces pain through CB2 receptors adds another non-psychoactive cannabinoid option for the pain-opioid equation.

Replication

Not stated in abstract.

Funding

Not reported in abstract.

Conflicts of interest

Not reported in abstract.

Questions still open

  • Would CBD reduce opioid misuse in human chronic pain patients? What's the optimal CBD dose and timing relative to opioid administration? Does CBD affect the rewarding properties of other addictive substances similarly?

Read the original research

Cannabidiol reduces oxycodone self-administration while preserving its analgesic efficacy in a rat model of neuropathic pain.

Scientific reports, 16(1), 2080

Scientific Reports is a reputable journal known for publishing high-quality research across various scientific disciplines.

Citation

Bruijnzeel, Adriaan W; Behnood-Rod, Azin; Chellian, Ranjithkumar; Malphurs, Wendi; Caudle, Robert M; Febo, Marcelo; Setlow, Barry; Murphy, Niall P; Neubert, John K. (2026). Cannabidiol reduces oxycodone self-administration while preserving its analgesic efficacy in a rat model of neuropathic pain.. Scientific reports, 16(1), 2080. https://doi.org/10.1038/s41598-025-31828-y

Explore the wider topic